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Stem from the promise of stem cells therapeutic potential for a number of diseases, the regenerative medicine is reaching en-
thusiastic proportions nowadays. Current therapies include drug treatment, lifestyle modification, organ transplantation, RNA 
interference “breakthrough technology”, and stem cell-based therapy. Research on stem cells is a multiplex challenge provok-
ing both the attention and the confusion of biologists, biotechnologists, medical specialists, and politicians. By integrating vari-
ous approaches of transcriptomics, proteomics and metabolomics, current adipobiology has identified more than 100 secretory 
proteins that are produced by the adipose tissue. These proteins designated adipokines include growth factors, cytokines, chem-
okines, neuropeptides and hypothalamic hormones/releasing factors. In addition, the adipose tissue’s secretome contains steroid 
hormones, free fatty acids, prostaglandins, and endocannabinoinds. Moreover, adipose tissue is the source of adipose-derived 
stem cells (ADSC). Current interest in the ADSC stems from their multilineage differentiation potential, and ease of derivation in 
larger quantities using less invasive methods, compared with other stem cell types. The possible benefits of ADSC-based therapy 
may be mediated via cell proliferation/differentiation and/or paracrine mechanisms. The present review, focusing on adipose 
tissue secretory activity, also highlights the possible implication of ADSC in the therapy of various disorders, particularly 
neurodegenerative diseases, myocardial infarction and stroke, along with gut and liver diseases. Biomed Rev 2010; 21: 57-63.
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INTRODUCTION
Crohn’s disease: a prototype of adipose tissue-related 
disease
Dr Burrill B. Crohn (1884-1983) with his colleagues Leon 
Ginzburg and Gordon Oppenheimer published an article en-
titled “Regional ileitis: a new clinical entity” in 1932 (cited 
in 1), the disease being later coined after his name. Notably, 
these three authors described hypertrophy of mesenteric adi-
pose tissue adjacent to the part of inflamed intestine. Insight-
fully, Mycobacterium avium paratuberculosis infection was 
etiologically linked to “Regional ileitis” by Crohn himself, 
now the story being revitalized (1). Arguably, the contribu-
tion of adipose tissue to the pathogenesis of infectious dis-
eases is gaining attention. For instance, adipose tissue is one 
of the major hosts of Trypanosoma cruzi infection in Chagas 
disease (2) and of Mycobacterium tuberculosis (3).
The present article attempts to review current concepts of 
adipose-derived stem cells (ADSC), focusing on adipose tis-
sue secretory activity, particularly its paracrine phenotype. 
We also highlight the possible implication of ADSC in the 
therapy of various disorders, particularly neurodegenerative 
diseases, myocardial infarction and stroke, along with gut 
and liver diseases. 
ADIPOSE TISSUE
At structural and functional level, white and brown adipose 
tissue (WAT and BAT, respectively) are traditionally distin-
guished. Although the function and topology of BAT have 
been re-evaluated recently (4,5), adipose tissue (“WAT” will 
be assumed from hereon) is generally partitioned into two 
main large depots with visceral and subcutaneous location, 
and many small depots associated with various organs in-
cluding heart, blood vessels, lymph nodes, eyes as well as 
parasellar region in the brain and epidural space in the spi-
nal cord. Adipose tissue is a dynamic system, consisting of 
adipocytes and non-adipocyte cellular elements, including 
stromal, vascular, nerve and immune cells. These cells may 
input, process, and output information, a sophisticated bio-
logical module resembling brain, particularly hypothalamus 
(6-8).
At birth, the average-size infant has approximately five 
billion adipocytes, whereas their total number becomes ap-
proximately 80 billion in adults. Adding more than billion 
fibroblasts, mast cells, lymphocytes, dendritic cells and mac-
rophages makes the whole body adipose tissue a major secre-
tory organ of humans. Adipose tissue modulates whole body 
metabolism by controlling insulin sensitivity and circulating 
glucose and fatty acid levels in tissues such as muscle, liver 
and brain (8-15). 
The most momentous challenge that has occurred in the 
field of adipose tissue research has been the discovery of lep-
tin (from Greek leptos, meaning thin), an adipocyte-secreted 
Ob gene-encoded protein, in the end of 1994 (8). This be-
came an acute trigger for the current development of adipo-
biology, particularly for the studies on cell protein secretion 
in adipose tissue (10,13-15). Hence the current paradigm 
framed by the two Nobel Prize winners George Palade and 
Gűnder Blobel regarding the rough endoplasmic reticulum-
Golgi complex secretory pathway and the signal hypothesis, 
respectively, began to be explored in adipose tissue secretion, 
demonstrating that not only adipocytes but also other adipose 
cell types express a high secretory phenotype (9-16). For in-
stance, 259 proteins were identified in the cultured human 
visceral adipose tissue 108 of them being secretory proteins 
(14), that is, bearing a N-terminal secretion signal peptide. 
Likewise, another in-depth proteome study on 3T3-L1 adi-
pocytes identified 3 287 proteins (11), at present the largest 
proteome map of adipocytes.
According to current cell biology understanding, the 
process of protein secretion is mediated by synthesis, post-
translational modification and folding (in the lumen of rough 
endoplasmic reticulum), sorting and targeting to final desti-
nations such as plasma membrane, nucleus, intracellular or-
ganelles, and exocytosis. Briefly, the three major types of se-
cretory proteins are plasmalemmal, intracellular (imported) 
and exported proteins (reviewed in 13,15,17), the adipokines 
being an example of the latter class of secretory proteins. 
Further, non-rough endoplasmic reticulum-Golgi complex 
pathways using multivesicular endosome-derived exosomes 
and plasmalemma-shedding microparticles termed ectos-
omes are also appreciated in recent studies on adipo-secre-
tion (15,16,18). Hence, both exosomes and ectosomes should 
also be considered the constituents of adipocyte secretome. 
Importantly, through endocrine and paracrine pathways these 
nano-sized structures translocate several membranes, cy-
tosolic and nuclear proteins as well as adiponectin, exosomes 
being recently coined “adiposomes” (18). 
In effect, systems adipobiology approach with integrated 
transcriptomics, proteomics and metabolomics identified 
more than 100 secretory (endocrine and paracrine) proteins 
designated adipokines (9-15). Trayhurn and Wood (10) con-
ceptualized the proteome of adipose tissue as adipokinome, 
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whereas the whole spectrum of adipose secretory products 
was designated secretome, the latter embodying both pro-
teins (adipokines) and non-proteins such as free fatty acids, 
steroid hormones (19), endocannabinoids (20) and nitric ox-
ide (21) among others. Using current methodologies of adi-
poproteomisc (11,14,15), many newcomers are expected to 
arrive to adipose secretome.
Noteworthy, hypothalamic hormones/releasing factors, 
neuropeptides and neurotrophic factors are also synthesized 
and released from adipose tissue (6,7 and references therein) 
In effect, all components of adipose secretome may contrib-
ute to the regulation of numerous biological functions (ap-
petite, satiety, energy homeostasis, lipid and glucose me-
tabolism, inflammation, immunity, hemostasis, reproduction, 
aging, learning and cognition) as well as the pathogenesis 
of cardiometabolic (9,12,13,22,23), gastrointestinal (24-27), 
neurodegenerative (28-31) and other diseases (9,13) (Table 
1). 
In brief, the adipose tissue secretome is a potent producer 
of multiple pleiotropic factors; adipokines with a possible 
neuroregenerative potential are listed in Table 2. From the 
perspective of regenerative medicine, such a super-sized se-
cretome may allow transplanted ADSC to exert a strong para-
crine activity over the injured tissue. With the use of various 
bioengineering technologies, this activity may be directed in 
a tissue- and disease-specific manner. 
ADIPOSE-DERIVED STEM CELLS
“In science, as in life, there seem to be three kinds of prob-
lems, which we classify as “easy”, “difficult”, or “impossi-
ble”. “Easy” problems in science are those in which concept 
and methodology both appear to be adequate; “difficult” 
problems are those in which either concept and/or methodol-
ogy appears to be deficient; “impossible” problems are im-
possible” –in 1964, the famous Oscar Hechter, together with 
Halkerston, wrote in their review “On the action of mam-
malian hormones” (32). In our present case dealing with the 
adipose secretome in ADSC-based therapy, the problem may 
be classified as a difficult, but not impossible problem. 
Although the currently popular concept of stem cells can 
be traced back to the end of the 19th century (reviewed in 
33), the potential of ADSC in regenerative medicine has only 
been appreciated recently (34-45). 
Different stem cell populations have been intensively 
studied in the last decade as a potential source of new cells, 
for example, cardiomyocytes that can ameliorate the injured 





















Table 2. Selected list of “neuroregenerative” adipokines*
Nerve growth factor 
Brain-derived neurotrophic factor 
Ciliary neurotrophic factor 
Glial cell line-derived neurotrophic factor
Vascular endothelial growth factor 
Hepatocyte growth factor
Transforming growth factor-β
Granulocyte and macrophage colony stimulating 
factors
Angiopoietin-1 






* For references (6,7,66,68-70). 
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myocardium and eventually restore cardiac contractility, neu-
ral cells that can rescue injured brain and peripheral nerves. 
Stem cells can generally be classified into embryonic and 
adult form; a variation of the former is so-called induced 
pluripotent stem (iPS) cells, whereas bone marrow-, umbili-
cal cord- and placenta-derived stem cells as well as ADSC 
and skin progenitor cells are examples of adult stem cells. 
For a long time, embryonic stem cells were thought to be 
the only source of pluripotency, a dogma that has been chal-
lenged during the last decade. The derivation of human stem 
cells from pre-implantation embryos (specifically, from the 
inner cell mass of the human blastocyst at day 5 or 6 of the 
early embryo development) raised great expectations for 
their use in regenerative therapy (33). However, ethical con-
cerns, teratocarcinomas formation upon transplantation and 
immunological risks became serious limitations at the clini-
cal settings. A feasible alternative option might be provided 
by auto-transplantation of ADSC or skin-derived precursor 
cells as easily accessible and ethically acceptable source of 
stem cells. 
The stromal vascular fraction of adipose tissue contains 
stem cells, T-lymphocytes, anti-inflammatory macrophages, 
endothelial precursor cells, and preadipocytes. In cell cul-
ture conditions, ADSC display an impressive developmental 
plasticity, including a multilineage differentiation potential; 
they can differentiate into bone, cartilage, muscle and neu-
ronal cells (46-55). In addition, the ADSC are capable of ex-
pressing cholinergic molecules which could be a great news 
for reducing the burden of Alzheimer’s disease (41). Note-
worthy, a subset of adipocytes may originate from the neural 
crest cells (46,47). 
Adipose-derived stem cells can be obtained by a less in-
vasive method and in larger quantities compared with bone 
marrow-derived stem cells and neural stem cells. By lipo-
suction, a common surgical operation, adipose tissue can be 
harvested in large quantities with minimal side effects from 
several regions of the body. On average, 100 ml of human 
adipose tissue yields about 1 x 106 stem cells, or about 5 x 
105 stem cells could be obtained from 400 to 600 mg adipose 
tissue (35,36,43). Also, the flow cytometry analysis has pre-
viously reported that ADSC express high levels of stem cell-
related antigens (CD13, CD29, CD44, CD105, and CD166) 
and stem cell-related transcription factors. 
Understanding signaling pathways that drive prolif-
eration, transdifferentiation and secretion of ADSC is of 
great importance for controlling their behavior. Applying 
efficient cell engineering protocols including encapsula-
tion (for example, in microspheres) of various “stem cell 
growth factors” released into the medium of cultured ADSC 
may encourage their tissue-specific differentiation poten-
tial. Understanding various approaches involving both the 
transduction and the pharmacology of ADSC could further 
boost their utility. For instance, (i) stem cells transduced 
with tyrosine hydroxylase and other related genes could 
function as biological minipumps to enhance the dopamin-
ergic neurotransmission after grafting (56), (ii) lovastatin, 
a cholesterol-lowering drug (57), and berberine, a plant 
antioxidant (58), both prevent ischemia-induced apoptosis 
in mesenchymal stem cells, and (iii) valproic acid (an anti-
convulsant, mood-stabilizing and anticancer drug exerting 
histone deacetylase inhibitory action) affects neural stem 
cell proliferation (59) .
ADSC: AN OLD REMEDY? 
Recent evidence shows that Homo obesus (60, cf. 61,62) 
is much prone to expressing a surprisingly high number of 
diseased phenotypes, including those discussed herein (24-
31,63-65). Symbolically, if ADSC transplantation may in-
deed bring therapeutic effects in patients, this might be a 
science-based rescue of the obese humans suffering from 
various cardiometabolic and neurodegenerative diseases. In-
deed, reminding us of similia similibus curantur (from Latin, 
meaning “like cures like”), a homeopathic axiom introduced 
by Dr Samuel Hahnemann (1755-1843) in the first edition of 
his book The Organon of the Healing Art.
 In conclusion, considering the ease of derivation and 
ethical aspects, ADSC could indeed be a better source of 
stem cell (66) than bone marrow-derived stem cells (67). 
Translated into the topic of present review, this may sound 
as follows: adipose secretome is better secretome than bone 
marrow secretome. In brief, the regenerative potential of 
ADSC’s secretome requires further investigation and ap-
preciation.
 Altogether, “the mechanisms we have proposed may be 
incorrect, but they can be tested; if found untenable, they 
can only be replaced by “better” mechanisms” – Hecther and 
Halkerston wrote in their 119 page-long chapter (32).
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